ELAVL1 and acute respiratory distress syndrome: Inhibiting the ELAVL-1/HuR -GSK3β axis, especially at the level of GSK3β as there several GSK3β inhibitors already in clinical practice [38], could be an intriguing, novel approach to ARDS therapy as it directly targets one of the major underlying pathomechanisms of the disease.